Affiliation: British Columbia
- Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriersEitan Friedman
The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Breast Cancer Res 8:R15. 2006....
- Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomyA Fuchsia Howard
School of Population and Public Health, University of British Columbia, Canada
BMC Womens Health 10:24. 2010..Women's perspectives on the timing of these decisions are not well understood. Accordingly, the purpose of this research was to describe how women construct the 'right time' to consider decisions about RRM and RRO...
- Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient databaseCharmaine Kim-Sing
Radiation Oncology, BC Cancer Agency, Vancouver BC, Canada
Int J Radiat Oncol Biol Phys 60:463-9. 2004..To investigate timing of intervention for solitary biochemical relapse following external beam radiation therapy (EBRT) for localized prostate cancer, and to assess the impact on survival...
- Waist-to-hip ratio and breast cancer mortalityMarilyn J Borugian
Cancer Control Research Program, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Am J Epidemiol 158:963-8. 2003..Elevated WHR was confirmed as a predictor of breast cancer mortality, with menopausal status and ER status at diagnosis found to be important modifiers of that relation...
- Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer?Marilyn J Borugian
Cancer Control Research, British Columbia Cancer Agency, Vancouver, Canada
Cancer Epidemiol Biomarkers Prev 13:1163-72. 2004..8; 95% CI, 1.3-18.1, comparing highest to lowest quartile). Higher dietary protein intake was associated with better survival for all women (relative risk, 0.4; 95% CI, 0.2-0.8, comparing highest to lowest quartile)...
- PSA failure and the risk of death in prostate cancer patients treated with radiotherapyWinkle Kwan
Radiation Therapy Program, Fraser Valley Centre, British Columbia Cancer Agency, Surrey, British Columbia, Canada
Int J Radiat Oncol Biol Phys 60:1040-6. 2004..To determine the relationship between prostate-specific antigen (PSA) failure and cause-specific and overall survival in prostate cancer patients treated with radical radiotherapy...
- Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time biasTom Pickles
Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
Int J Radiat Oncol Biol Phys 57:11-8. 2003....
- Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapyHoward Huaihan Pai
Radiation Oncology Program, British Columbia Cancer Agency Vancouver Island Centre, Victoria, British Columbia, Canada
Int J Radiat Oncol Biol Phys 65:990-8. 2006..To investigate whether hemoglobin (Hb) levels affect outcome in men with localized prostate adenocarcinoma (LPA) treated with neoadjuvant androgen-suppression therapy (NAST) and external-beam radiotherapy (EBRT)...
- Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos
Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Room 750, 790 Bay Street, 7th Floor, Toronto, ON M5G 1N8, Canada
Breast Cancer Res Treat 105:221-8. 2007..Nonetheless, BRCA mutation carriers opting for a prophylactic oophorectomy as a breast and/or ovarian cancer risk-reducing strategy should complete childbearing prior to age 40 when this prevention modality is most effective...
- Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study GroupKelly A Metcalfe
Lawrence Bloomberg Faculty of Nursing, University of Toronto, Canada
J Clin Oncol 26:1093-7. 2008..To evaluate the rate of prophylactic contralateral mastectomy in an international cohort of women with hereditary breast cancer and to evaluate the predictors of uptake of preventive surgery...
- International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriersKelly A Metcalfe
Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada
Int J Cancer 122:2017-22. 2008..Approximately one-half of women at risk for breast cancer rely on screening alone...
- Hormone therapy and the risk of breast cancer in BRCA1 mutation carriersAndrea Eisen
Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
J Natl Cancer Inst 100:1361-7. 2008....
- Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an updateJacek Gronwald
Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical Academy, Szczecin, Poland
Int J Cancer 118:2281-4. 2006..83; 95%CI, 0.24-2.89) but this subgroup was small. In contrast, a strong protective effect of tamoxifen was apparent among women who were premenopausal or who had undergone natural menopause (OR = 0.44; 95% CI, 0.27-0.65)...
- Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersSteven A Narod
The Centre for Research on Women s Health, University of Toronto, 790 Bay Street, Toronto, Ontario M5G 1N8, Canada
J Natl Cancer Inst 94:1773-9. 2002..We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2...
- A comparison of bilateral breast cancers in BRCA carriersJeffrey N Weitzel
The Centre for Research in Women s Health, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8
Cancer Epidemiol Biomarkers Prev 14:1534-8. 2005..It is generally believed that the two cancers represent independent events. However, the extent of concordance between the first and second tumors with respect to hormone receptor expression and other pathologic features is unknown...
- Rapid progression of prostate cancer in men with a BRCA2 mutationS A Narod
Women s College Research Institute, 790 Bay Street, 7th Floor, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada
Br J Cancer 99:371-4. 2008..0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation...
- Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriersCarey A Cullinane
City of Hope National Medical Center, Duarte, CA, USA
Int J Cancer 117:988-91. 2005..Among BRCA2 carriers, increasing parity was associated with a significant increase in the risk of breast cancer before age 50 and this increase was greatest in the 2-year period following a pregnancy...
- Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriersAndre Nkondjock
Epidemiology Research Unit, Research Centre, Centre Hospitalier de Universitaire de Montréal, CHUM Hotel Dieu, Montreal, Canada
Int J Cancer 118:103-7. 2006..These results suggest that among women with BRCA gene mutation, coffee consumption is unlikely to be harmful and that high levels of consumption may in fact be related to reduced breast cancer risk...
- Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos
Centre for Research in Women s Health, University of Toronto, Women s College Hospital, 790 Bay Street, 7th Floor, Totonto, Ontario M5G 1N8, Canada
Cancer Causes Control 16:667-74. 2005..46; 95% CI 0.30-0.69). This study implicates early age at menarche as a determinant of breast cancer among women with a BRCA1 mutation...
- Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 MutationAmy Finch
Centre for Research in Women's Health, Toronto-Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
JAMA 296:185-92. 2006....
- Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos
Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Toronto, ON, Canada
Breast Cancer Res 7:R833-43. 2005..We asked whether there is an association between changes in body weight and the risk of breast cancer in women who carry a mutation in either breast cancer susceptibility gene, BRCA1 or BRCA2...
- Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control studySteven A Narod
Centre for Research on Women s Health, University of Toronto, Ontario, Canada
Lancet Oncol 7:402-6. 2006..We aimed to assess whether exposure to ionising radiation through mammography screening was associated with risk of breast cancer in BRCA1 or BRCA2 mutation carriers...
- Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control studyAndrea Eisen
Toronto Sunnybrook Regional Cancer Center, Toronto, ON, Canada
J Clin Oncol 23:7491-6. 2005....